Evidence · Randomised trial
Recombinant human erythropoietin improves neurological outcomes in very preterm infants.
- Anaemia and transfusion
- Intraventricular haemorrhage and white matter injury
- Jaundice and haematology
- Medical
- Neurodevelopmental follow-up
- Neurology
This paper is from 2016, more than five years ago. Newer evidence may have been published since.
Summary
This randomised placebo-controlled trial evaluated repeated low-dose recombinant human erythropoietin given intravenously within 72 hours of birth and then every other day for two weeks in infants born at or before 32 weeks' gestation. The primary outcome was death or moderate to severe neurological disability at 18 months corrected age. The authors report a reduced risk of the primary outcome in the erythropoietin group with no obvious adverse effects. It is relevant to clinicians considering neuroprotective strategies in very preterm infants.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.